Evaxion A (EVAX) Asset Utilization Ratio (2025 - 2026)
Evaxion A (EVAX) reported Asset Utilization Ratio of 1422.0 for Q1 2026, up 814407.2% on a YoY basis from N/an in Q1 2025, and up 11.71% quarter-over-quarter from 1272.94 in Q4 2025.
Evaxion A (EVAX) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
Evaxion A has reported Asset Utilization Ratio for 2 years, with the latest figure at 1422.0 in Q1 2026.
- For the quarter ending Q1 2026, Asset Utilization Ratio rose 814407.2% year-over-year to 1422.0; the trailing twelve-month figure through Mar 2026 stood at 1422.0 (up 814407.2% YoY), and the FY2025 full-year result was 0.37, up 39.69% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 1422.0, up from 1272.94 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 1551.88 in Q2 2025, with the low at 0.17 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 0.55 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.60 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 1,422.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 0.37 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,422.00 |
| Dec 31, 2025 | 1,272.94 |
| Sep 30, 2025 | 1,418.30 |
| Jun 30, 2025 | 1,551.88 |
| Mar 31, 2025 | 0.17 |